British Business Bank

"As a trusted advisor to financial services boards, I kept seeing the same pattern: teams got excited about the potential of generative AI but then hit a wall when asked about governance and compliance. We founded Vigilant AI.ai because the toolset to answer those questions simply didn’t exist. Our platform enables people in the business to onboard AI Teammates where work happens whilst real-time guardrails and audit logs protect and govern. Customers gain AI productivity at speed, with regulatory compliant trust."

"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier. This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."

"JECO was born out of the belief that if developers are given frictionless ways to improve and enhance their development processes, they can find quicker, cost effective routes to market, and can also start to play an important role in addressing wider environmental issues that may impact our industry in the future. I am incredibly grateful to all our investors for supporting us in our mission; to support developers in making positive behavioural changes through the power of technology."

"Portal Biotech’s technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level on accessible desktop instruments that bring this state-of-the-art characterisation to any lab. These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing."

"Ten years ago, I began combining financial modeling expertise with computational biology to create a drug discovery platform. Evolution has spent billions of years perfecting natural defense mechanisms, and now we’re using AI to unlock this wisdom. This isn’t just professional for me; my father died from a drug-resistant infection our healthcare system couldn’t treat. At Queen’s, I built AMPLY to tackle deadly diseases differently, creating technology that will save lives when current treatments fail."

"Acquiring banks and most businesses were built for the one-to-one transactions of Commerce 1.0. However, in the era of Commerce 2.0, where transactions within a single marketplace involve numerous parties, financial institutions are struggling to deliver payment operations that meet the evolving needs of their customers. As a result, they’re unable to compete with the likes of Stripe Connect and Adyen whose solutions currently dominate the payments ecosystem despite high fees, complicated integrations, poor support, and prolonged payment wait times. At Ryft, we have the technology that allows acquiring banks to overcome these hurdles and we’re actively exploring several strategic partnerships to solve this issue in the payments industry."

"Technology enabled product sampling is an exciting and fast growing market. Triyit is well positioned in the space with a strong consumer following and traction gained with a number of well known, established brands. The company has achieved impressive growth to date, and we look forward to supporting Alex and the team as they embark on the next stage of their strategy."

"Unlike vehicle assembly, where processes are repeatable, with aircraft the need for lightweight components and high precision means that no two operations are the same. For this reason automation has so far proved too difficult or too costly. Our robot guidance systems overcome these challenges. The investment from the Midlands Engine Investment Fund II will enable us to consolidate our position and start work on the next generation of products to ensure we maintain our position as thought leaders in the industry."

"Over the past 12 months, we have been building out a series of non-custodial, on-chain products, creating a whole new type of crypto payment,"

"We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry. On the back of a very successful year for Cytomos, this new funding will now allow us to scale up our engagement with industry partners. We truly believe that, through our CDS technology, we offer a powerful platform which will help the scientific community bring novel therapies to market faster and radically reduce costs by making better informed, game-changing decisions a lot earlier."

"This investment is key to the next level of growth within our business. The next 12 months are going to be very exciting, seeing us reach other markets and geographies with a product that is always innovating for the good of our customers."

"We are in a great position to resume our exponential growth now. I feel confident that we are bouncing back strongly"

"We are excited to announce this latest funding round and overwhelmed with the drive and support behind the Seedr campaign. We go into 2021 with a strong proposition as we continue using the power of Open Banking technology to drive our product innovation."

"We’ve had a great first year with over 300 e-commerce stores from 23 different countries choosing Machine Labs to increase their sales,"